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SUMMARY
Melanoma accounts for more than 80% of skin can-
cer-related deaths, and current therapies provide
only short-term benefit to patients. Here, we show
in melanoma cells that maternal embryonic leucine
zipper kinase (MELK) is transcriptionally upregulated
by the MAPK pathway via transcription factor E2F1.
MELK knockdown or pharmacological inhibition
blocked melanoma growth and enhanced the effec-
tiveness of BRAFV600E inhibitor against melanoma
cells. To identify mediators of MELK function, we
performed stable isotope labeling with amino acids
in cell culture (SILAC) and identified 469 proteins
that had downregulated phosphorylation after
MELK inhibition. Of these proteins, 139 were previ-
ously reported as substrates of BRAF or MEK,
demonstrating that MELK is an important down-
streammediator of theMAPK pathway. Furthermore,
we show that MELK promotes melanoma growth
by activating NF-kB pathway activity via Sequesto-
some 1 (SQSTM1/p62). Altogether, these results un-
derpin an important role for MELK in melanoma
growth downstream of the MAPK pathway.
INTRODUCTION
Melanoma is the deadliest form of skin cancer, accounting for
80% of skin cancer-related deaths (Miller and Mihm, 2006).
More than 85% of melanomas are caused by mutations in
BRAF or NRAS genes and mutation or deletion of the NF1
gene (Cancer Genome Atlas Network, 2015). These alterations
can activate the mitogen-activated protein kinase (MAPK)
pathway, which in turn promotes proliferation and facilitatesmel-
anoma initiation and progression (Downward, 2003; Karnoub
and Weinberg, 2008; Wellbrock et al., 2004a, 2004b).
After the initial discovery ofBRAFmutations in a large percent-
age of melanomas (Davies et al., 2002), specific and highly effec-
tive small-molecule inhibitors that target either BRAF or MEK
mutants were developed and used to treat BRAF mutant meta-
static melanoma in clinics (Chapman et al., 2011; Flaherty
et al., 2012). BRAF inhibitors alone or in combination with MEK
inhibitors have shown some success; however, within months
of treatment, drug resistance emerges and renders these drugs
ineffective (Kim et al., 2013; Rizos et al., 2014; Shi et al., 2014).
The alternative approach of targeting the MAPK pathway in
NRAS mutant and NF1-deficient melanoma has not proved
effective (Ascierto et al., 2013; Whittaker et al., 2013). Similarly,
new immunotherapeutic approaches, such as anti-CTLA-4
antibody (ipilimumab) and anti-PD1 or anti-PD-L1 antibodies
(pembrolizumab or nivolumab), have benefited only a subset
of patients (Hodi et al., 2010; Postow et al., 2015; Robert
et al., 2015). Thus, new strategies for treating melanoma and
improving patient survival are needed.
Maternal embryonic leucine zipper kinase (MELK) is a serine/
threonine protein kinase that regulates cell cycle, stem cell
renewal, and apoptosis (Badouel et al., 2006; Davezac et al.,
2002; Jung et al., 2008; Nakano et al., 2005). MELK knockout
mice are viable and display no adverse phenotypes (Wang
et al., 2014). This information and the availability of small-mole-
cule inhibitors of MELK with anti-cancer activity in breast and
other cancers indicates that MELK might be a druggable target
for cancer cell-selective therapy (Gray et al., 2005; Kohler
et al., 2017; Nakano et al., 2005).
Here, we show that MELK is necessary for melanoma growth.
We found that MELK regulated the phosphorylation of a large
number of proteins, many of which were previously identified
as substrates of BRAF and/or MEK. We also demonstrate that
MELK regulation of the nuclear factor kB (NF-kB) pathway partly
mediates themelanoma-promoting activity of MELK. Altogether,
our studies identifyMELK as an important regulator of melanoma
growth downstream of the MAPK pathway.
RESULTS
MELK Is Overexpressed in Melanoma by the MAPK
Pathway
MELK is highly overexpressed in several cancer types, and its in-
hibition has been shown to block the tumor growth of some can-
cers (Inoue et al., 2016; Joshi et al., 2013; Kato et al., 2016;Wang
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Figure 1. MELK Is Upregulated in Melanoma by the MAPK Pathway through the Transcription Factor E2F1
(A and B) Indicated melanoma datasets were analyzed for MELK mRNA expression. Relative expression in patient-derived melanoma samples compared to
normal skin (A) and in N1+ versus N0 or primary versus metastatic melanoma (B) is shown.
(C)MELKmRNA expression wasmeasured after treatment with vemurafenib (2 mM) or trametinib (250 nM) for 24 hr. Relative mRNAMELK expression is plotted in
reference to DMSO-treated melanoma cell lines.
(D) MELK protein expression was measured by immunoblotting in indicated melanoma cell lines after treatment with DMSO (), vemurafenib (V; 2 mM), or
trametinib (T; 250 nM) for 24 hr. ACTINB was used as the loading control.
(E) mRNA expression for the indicated genes was measured in A375 cells 24 hr after DMSO, vemurafenib (2 mM), or trametinib (250 nM) treatment. mRNA
expression is shown relative to DMSO-treated A375 cells.
(legend continued on next page)
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et al., 2014, 2016). MELK knockout mice are viable and do not
show specific phenotypes (Wang et al., 2014). Therefore, MELK
appears to be a potentially effective and cancer cell-selective
target. The role of MELK in melanoma has not been studied,
and few MELK substrates have been identified thus far. There-
fore, we asked whether MELK plays a role in melanoma growth.
We first analyzed the expression ofMELK in previously published
geneexpressiondatasets of patient-derivedmelanomasamples.
MELKwas overexpressed in patient-derivedmelanoma samples
compared to normal skin samples (Figure 1A; Figures S1A–S1C).
In addition, MELK expression significantly increased with
spreading of melanoma, and metastatic melanoma had higher
MELK expression than primary melanoma (Figure 1B; Figures
S1B and S1C). A previous study identified increased expression
of MELK and other genes as a genetic signature that predicts
melanoma progression (Ryu et al., 2007). Altogether, these re-
sults suggest an important role for MELK in melanoma.
We aimed to decipher the mechanism of MELK overexpres-
sion in melanoma. One of the most altered signaling pathways
in melanoma is the MAPK pathway, which is constitutively active
in more than 85% of melanomas because of mutations in BRAF/
NRAS genes or inactivation of the NF1 gene (Cancer Genome
Atlas Network, 2015). Therefore, we asked whether the MAPK
pathway is necessary for transcriptional upregulation of MELK
inmelanoma.We treated threeBRAFmutantmelanoma cell lines
(A375, M14, and SKMEL-28) with the BRAFV600E inhibitor ve-
murafenib or the MEK inhibitor trametinib. Treatment of these
cells with either inhibitor reduced MELK mRNA (Figure 1C) and
protein (Figure 1D) levels. Altogether, these results demonstrate
that transcriptional upregulation of MELK inmelanoma is primar-
ily mediated by the MAPK pathway.
Transcription Factor E2F1 Is Required for
Transcriptional Upregulation of MELK in Melanoma
Cells
To determine the mechanism of transcriptional upregulation of
MELK, weanalyzed theMELKpromoter sequence usingPROMO
and rVista v.2.0. We identified conserved DNA binding sites for
E2F and MYC transcription factors. We then asked whether any
of these transcription factors were upregulated, like MELK, by
the action of the MAPK pathway. We treated A375 andM14 cells
with vemurafenib or trametinib and analyzed the expression of
E2F1-8 andMYC. OnlyMYC, E2F1, and E2F2 were significantly
downregulated after treatment with vemurafenib or trametinib
(Figure 1E; Figure S1D). Therefore, we individually knocked
down MYC, E2F1, and E2F2 in melanoma cell lines using short
hairpin RNAs (shRNAs) and analyzed the effect of these knock-
downsonMELKexpression. Knockdownof the transcription fac-
tor E2F1 significantly reduced MELK expression (Figures 1F and
1G), while E2F2 orMYC knockdown did not (Figures S1E–S1H).
Next, we wanted to determine whether the transcription factor
E2F1 directly targets MELK. To this end, we cloned the MELK
promoter with an E2F1 DNA binding site upstream of a firefly
luciferase reporter gene. This MELK-FLuc construct was tested
for responsiveness to the BRAF inhibitor vemurafenib. A375 cells
transfected with the MELK-FLuc construct had reduced lucif-
erase activity after vemurafenib treatment (Figure 1H). We also
mutated the E2F1 DNA binding site on the MELK promoter and
observed a substantial reduction of MELK promoter-driven re-
porter activity, making this construct non-responsive to vemura-
fenib treatment (Figure 1H). Finally, to determine whether E2F1
directly associates with the MELK promoter in vivo, we per-
formed chromatin immunoprecipitation (ChIP). We treated
A375 cells with vemurafenib, or with DMSOas a control, and per-
formed ChIP for E2F1 for theMELK promoter, or for the GAPDH
promoter as a control. E2F1 was significantly enriched at the
MELK promoter compared to the negative control GAPDH pro-
moter (Figure 1I). In addition, E2F1 binding of theMELK promoter
was inhibited by vemurafenib treatment (Figure 1I). Altogether,
these results demonstrate that the MAPK pathway stimulates
E2F1 expression, which in turn activates MELK transcription by
directly binding to the MELK promoter in melanoma cells.
MELK Inhibition Blocks Melanoma Growth
Because MELK is a kinase that is highly expressed in melanoma
cells, we asked whether MELK is a potential target for mela-
noma therapy. To test whether MELK inhibition would block
melanoma growth, we treated melanoma cell lines with the
MELK inhibitor OTSSP167 (Chung et al., 2012; Kohler et al.,
2017; Wang et al., 2014). OTSSP167 treatment significantly in-
hibited melanoma cell line proliferation (Figure 2A) and colony
formation in a soft-agar assay (Figures 2B and 2C; Figure S2).
To confirm that the growth inhibition was due to MELK inhibition
and not an off-target effect, we treated cells with a secondMELK
inhibitor, MELK-8a (Toure´ et al., 2016). Consistent with our re-
sults with OTSSP167, MELK-8a inhibited melanoma cell growth
in both the proliferation assay (Figure S3A) and the soft-agar
assay (Figures S3B and S3C).
To determine whether the ability of MELK to promote mela-
noma growth was dependent on its kinase activity, we per-
formed rescue experiments with a wild-type MELK open reading
frame or a kinase dead MELK mutant (MELK-D150A). Only wild-
type MELK, not the kinase dead mutant, was able to rescue
growth in the soft-agar assay, showing that the kinase activity
of MELK is required for its ability to promote melanoma growth
(Figures 2D and 2E; Figures S3D and S3E).
(F) A375 cells expressing either E2F1 or non-silencing (NS) shRNA were analyzed for E2F1 (left) or MELK (right) mRNA expression using qRT-PCR. mRNA
expression in E2F1 shRNA-expressing cells is shown relative to NS shRNA-expressing cells.
(G) Indicated protein levels were monitored in A375 cells expressing either E2F1 or NS shRNAs. ACTINB was used as a loading control.
(H) Relative MELK promoter-driven firefly luciferase (MELK-F-Luc) activity is shown in A375 cells treated with DMSO or vemurafenib and transfected with or
without a mutated E2F1 DNA binding site containing the MELK-FLuc construct.
(I) A375 cells treated with DMSO or vemurafenib (2 mM) for 24 hr were analyzed for E2F1 recruitment on either the MELK or GAPDH promoter by chromatin
immunoprecipitation assay. Immunoglobulin G (IgG) antibody was used as a negative control. Percentage of enrichment relative to input under indicated
conditions is shown.
Data are presented as ±SD for three biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1.
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MELK Inhibition Blocks the Growth of Vemurafenib-
Resistant Cells and Delays the Emergence of
Vemurafenib Resistance
Our results showed that MELK is a downstream target of the
MAPK pathway and that MELK inhibition blocks melanoma
growth. Therefore, we asked whether vemurafenib-resistant
melanoma cell lines could also be inhibited by MELK inhibitors.
We analyzed A375 and SKMEL-239 parental cell lines
and vemurafenib-resistant versions of these two cell lines.
To test the effectiveness of MELK inhibitors for blocking
Figure 2. MELK Inhibition Blocks Melanoma Cell Growth in Culture
(A) Melanoma cell lines (A375, SKMEL-28,M14, YUGASP, andMeWo) were treatedwith indicated concentrations of OTSSP167 and analyzed for cell proliferation
using the MTT assay. Relative proliferation (%) for each melanoma cell line relative to DMSO-treated cells is shown.
(B) Melanoma cell lines (A375, SKMEL-28, M14, YUGASP, and MeWo) were treated with indicated concentrations of OTSSP167 and analyzed for anchorage-
independent growth using the soft-agar assay. Representative images for indicated melanoma cell lines under indicated treatment conditions are shown.
(C) Relative colony size (%) for indicated cell lines at indicated treatment conditions is shown.
(D and E) A375 cells expressing doxycycline-inducible MELK shRNA#1 (D) and MELK wshRNA#2 (E) were infected with virus for expression of either MELK
wild-type (WT) or MELK knockdown (KD), grown without or with doxycycline, and analyzed for soft-agar colony formation. Representative images are shown.
Scale bars, 200 mm. Data are presented as ±SD for three biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S2 and S3.
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vemurafenib-resistant cell lines, we treated parental and vemur-
afenib-resistant A375 and SKMEL-239 cell lines with vemurafe-
nib alone or with MELK inhibitors (OTSSP167 and MELK-8a).
Treatment of parental cell lines (A375 and SKMEL-239)
with either vemurafenib or MELK inhibitors (OTSSP167 and
MELK-8a) inhibited proliferation and growth in soft agar (Figures
3A–3F; Figure S4). In vemurafenib-resistant cell lines, vemurafe-
nib did not inhibit proliferation or growth in soft agar, but treat-
ment with MELK inhibitors (OTSSP167 and MELK-8a) did inhibit
proliferation and growth in soft agar (Figures 3A–3F; Figure S4).
Finally, we asked whether MELK inhibition can forestall the
emergence of vemurafenib resistance. We treated parental
A375 melanoma cells with vemurafenib alone or in combination
with OTSSP167 and performed a clonogenic assay to measure
the emergence of vemurafenib resistance. After 6 weeks of treat-
ment with these drugs, we visualized and quantified the number
of drug-resistant clones. Treating A375 cells with vemurafenib
produced several vemurafenib-resistant colonies (Figure 3G).
Combined vemurafenib and OTSSP167 treatment did not yield
drug-resistant colonies (Figure 3G). Altogether, these results
demonstrate that MELK inhibition can inhibit the growth of
vemurafenib-resistant melanoma and that the combination of
vemurafenib and OTSSP167 can forestall the emergence of ve-
murafenib resistance.
SILAC Identifies Cellular Substrates of MELK
MELK is a serine/threonine kinase for which few substrates are
known. Therefore, to comprehensively identify MELK sub-
strates, we performed a global phosphoproteomic analysis us-
ing stable isotope labeling with amino acids in cell culture
(SILAC). There were two major goals for this experiment:
(1) to characterize the diversity of proteins that are phosphor-
ylated by MELK in melanoma cells and (2) to identify the
potential pathway or pathways targeted by MELK to promote
melanoma growth. To achieve these goals, we used two
melanoma cell lines (A375 and M14) in which cell proliferation
is inhibited by MELK inhibition. These cell lines were cultured in
light medium, which contains light carbon (12C), light nitrogen
(14N), lysine, and arginine, or in heavy medium, which contains
heavy carbon (13C), heavy nitrogen (15N), lysine, and arginine.
After five cell doublings, incorporation of these amino acids
exceeded 95% (Table S1), cells in light medium were treated
with DMSO, and cells in heavy medium were treated with
MELK inhibitor OTSSP167 for 24 hr. SILAC analysis was
performed to identify potential MELK targets (Figure 4A). This
analysis identified 469 proteins with reduced phosphorylation
in both A375 and M14 cells on the same residues (Figure S5;
Tables S2, S4, and S5). A comparative analysis showed that
139 substrates identified by our SILAC analysis were previ-
ously identified as MAPK pathway substrates (Figure 4B;
Tables S2, S4, and S5) (Galan et al., 2014; Stuart et al.,
2015). This was not due to reduced MAPK signaling, because
OTSSP167 treatment did not inhibit ERK1/2 phosphorylation
(Figure S6A). We consider this to be an important observation
based on our findings that the MAPK pathway regulates
MELK expression and might mediate a large part of the mela-
noma growth and progression-promoting effect of the MAPK
pathway.
We next analyzed the SILAC data to predict the preferred
amino acid motif for MELK-induced phosphorylation by a newly
developed method. The identified MELK recognition site was
broad, and most MELK-mediated phosphorylation of identified
substrates occurred at serine (Figures 4C and 4D).
Finally, to identify the key pathways regulated by MELK-medi-
ated phosphorylation, we performed Ingenuity pathway analysis.
We identified the NF-kB pathway as an enriched pathway (Fig-
ure 4E). In total, eight proteins involved in NF-kB pathway regu-
lation, which had decreased phosphorylation as a result of MELK
inhibition, were identified by our SILAC experiments in both A375
and M14 cell lines (Figure 4F). We decided to further study
MELK-mediated regulation of the NF-kB pathway because of
the previously described role for this pathway in promoting mel-
anoma tumor growth and progression (Dhawan and Richmond,
2002; Madonna et al., 2012; Ueda and Richmond, 2006).
MELK Regulates the NF-kB Pathway via SQSTM1/p62
Based on our SILAC and Ingenuity pathway analysis results, we
asked whether MELK had a role in regulating the NF-kB
pathway. Consistent with our SILAC results, treating A375 and
M14 melanoma cell lines with the MELK inhibitor OTSSP167
resulted in attenuated NF-kB signaling, as assessed by
decreased phosphorylation of NF-kB inhibitor alpha (IkBa) (Fig-
ure 5A). A similar reduction in NF-kB signaling was observed in
melanoma cells after MELK knockdown using doxycycline-
inducible shRNAs (Figure 5B). Furthermore, melanoma cell
lines that were treated with MELK inhibitor and cells that ex-
pressedMELK shRNAs both showed reduced luciferase activity
when transfected with a NF-kB-responsive reporter plasmid
(pGL4.32[luc2P/NF-kB-RE/Hygro]) (Figure 5C). Similarly, known
NF-kB transcriptional targets were downregulated after MELK
knockdown (Figure 5D) and after OTSSP167 treatment (Fig-
ure 5E). We also found that treatment with another MELK
inhibitor, MELK-8a, attenuated NF-kB pathway activity, as
determined by decreased phosphorylation of IkBa and by
decreased expression of NF-kB-responsive genes (Figures
S6B and S6C).
In our SILAC analysis, we identified Sequestosome 1
(SQSTM1) as a protein with decreased phosphorylation after
MELK inhibition. SQSTM1 has been shown to be involved in
the regulation of NF-kB signaling (Long et al., 2010; Wooten
et al., 2005; Zotti et al., 2014). SQSTM1 has also been shown
to be important for NF-kB-mediated tumorigenesis (Duran
et al., 2008). We hypothesized that MELK phosphorylates
SQSTM1 to stimulate the NF-kB pathway. To test this, we per-
formed co-immunoprecipitation (coIP) to detect whether MELK
interacts with and directly phosphorylates SQSTM1. Our coIP
experiments showed that SQSTM1 interacts with MELK (Fig-
ure 5F). Next, we performed an in vitro kinase assay using
recombinant MELK and SQSTM1 proteins, as described previ-
ously (Canman et al., 1998), to test whether MELK directly phos-
phorylates SQSTM1. Consistent with our SILAC experiments,
MELK directly phosphorylated SQSTM1 (Figure 5G). To confirm
that MELK inhibition reduced SQSTM1 phosphorylation, we per-
formed the in vitro kinase assay using the MELK inhibitors
OTSSP167 andMELK-8a. As anticipated, inhibition of MELK ac-
tivity led to decreased SQSTM1 phosphorylation (Figure 5H).
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Figure 3. MELK Inhibition Is Sufficient to Overcome Vemurafenib Resistance
(A–D) Parental and vemurafenib-resistant melanoma cell lines A375 and SKMEL-239 were treated with either DMSO or indicated concentrations of vemurafenib
(A and C for A375 and SKMEL-239, respectively) or OTSSP167 (B and D for A375 and SKMEL-239, respectively) and analyzed for proliferation using the MTT
assay. Relative proliferation (%) for each cell line relative to DMSO-treated cells is shown.
(E) Parental and vemurafenib-resistant melanoma cell lines A375 and SKMEL-239 were treated with 1 mM vemurafenib or 50 nM OTSSP167 and analyzed for
anchorage-independent growth by the soft-agar assay. Representative images for indicated melanoma cell lines under indicated treatment conditions are
shown. Scale bar, 200 mm.
(legend continued on next page)
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Based on these results, we examined the activity of NF-kB
pathway upon SQSTM1 knockdown. Similar to the effect of
MELK inhibition, shRNA-induced knockdown of SQSTM1 in-
hibited the NF-kB signaling pathway and expression of NF-kB
target genes (Figures 5I–5K).
Constitutively Active IKKb Partially Rescues NF-kB
Signaling and Melanoma Growth after MELK Inhibition
Because inhibitor of NF-kB kinase subunit beta (IKKb) acts
downstream of SQSTM1, we asked whether overexpression
of constitutively active IKKb (IKKb CA) could rescue the inhibi-
tion of NF-kB signaling caused by MELK and SQSTM1
inhibition. Ectopic expression of IKKb CA partially rescued
impaired NF-kB signaling caused by MELK inhibition and by
(F) Relative colony size (%) for indicated melanoma cell lines at indicated treatment conditions is shown.
(G) A375melanoma cells were treatedwith 2 mMvemurafenib alone or in combination with 50 nMOTSSP167 over four weeks. Images of representative plates and
surviving colonies or cells are shown.
Data are presented as ±SD for three biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4.
Figure 4. SILAC Analysis Identifies MELK
Targets
(A) Schematic representation of the major steps
of SILAC analysis to identify phosphopeptides
that are altered after treatment with MELK
inhibitor OTSSP167 in melanoma cell lines (A375
and M14).
(B) Venn diagram showing commonly identified
proteins that overlap with previously identified
BRAFV600E and MEK targets.
(C) Consensus site for the MELK-mediated
phosphorylation amino acid recognition motif is
shown.
(D) Consensus site for the MELK-mediated
phosphorylation recognition motif based on
amino acid hydrophobicity is shown.
(E) Ingenuity pathway analysis of the MELK tar-
gets identified by SILAC analysis revealed eight
NF-kB regulatory proteins that showed down-
regulated phosphorylation after treatment with
MELK inhibitor OTSSP167.
(F) Site of phosphorylation on NF-kB regulatory
proteins for which reduced phosphorylation was
observed in SILAC for melanoma cell lines A375
and M14 after treatment with MELK inhibitor
OTSSP167.
See also Figure S5 and Tables S1, S2, S4, and S5.
downregulation of MELK expression,
as assessed by phosphorylation of
IkBa- and NF-kB-responsive reporter
activity (Figures 6A–6C). Expression of
IKKb CA also rescued the effects of
SQSTM1 knockdown in melanoma
cells, which indicates that the NF-kB
pathway is a downstream effector of
SQSTM1 function (Figure 6D).
To determine whether forced NF-kB
pathway activation in melanoma cells
could also rescue the melanoma growth
inhibition caused by MELK inhibition, we expressed IKKb CA in
the A375 melanoma cell line and analyzed the growth of mela-
noma cells in soft-agar assay. Overexpression of IKKb CA
stimulated the growth of A375 cells in soft agar, even in the
presence of the MELK inhibitor OTSSP167 (Figures 6E and
6F). Similarly, overexpression of IKKb CA restored the growth
of A375 melanoma cells in the presence of the second MELK
inhibitor MELK-8a (Figure S6D). In contrast, expression of an
empty vector in the presence of OTSSP167 or MELK-8a did
not rescue the growth of A375 cells (Figures 6E and 6F; Figures
S6D and S6E). Altogether, these results demonstrate that
attenuation of NF-kB signaling is partly responsible for
blocking melanoma growth inhibition after MELK inhibition
(Figure 7).
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Figure 5. MELK Regulates the NF-kB Pathway via SQSTM1
(A) A375 and M14 cells were treated with OTSSP167 (50 nM) for 24 hr and analyzed for indicated proteins by immunoblot analysis. ACTINB was used as the
loading control.
(B) A375 cells expressing doxycycline-inducible MELK shRNAs that were either untreated or treated with doxycycline (2 mg/mL) and analyzed for indicated
proteins by immunoblot analysis. ACTINB was used as loading control.
(legend continued on next page)
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DISCUSSION
In this study, we show that MELK is important for melanoma
growth that functions partly by facilitating NF-kB pathway activ-
ity. Our study allows us to draw several important conclusions.
First, MELK expression was activated by the MAPK pathway
and was necessary for melanoma growth. Second, we unex-
pectedly found that MELK phosphorylated many proteins that
were previously reported to be BRAF or MEK substrates. Third,
MELK inhibition blocked the growth of melanoma that was resis-
tant to the BRAF inhibitor vemurafenib. Finally, MELK regulation
of the NF-kB pathway occurred via SQSTM1, partly accounting
for its role in promoting melanoma growth. These results are
important because they describe a role for MELK in melanoma
as a survival kinase. This work also demonstrates that pharma-
cological inhibition of MELK with a highly potent MELK inhibitor
can exert strong inhibitory effects on tumor growth in a variety of
melanoma types, including NRAS mutant, NF1-deficient, and
vemurafenib-resistant melanoma.
MELK Inhibition Blocks Melanoma Growth
Melanoma is an aggressive form of skin cancer, as illustrated by
a 5-year survival rate of only 15%–20% for stage IV melanoma
(Sandru et al., 2014). Only a fraction of patients experiences
long-term benefits from current targeted therapies and immuno-
therapies (Johnson and Sosman, 2015). Therefore, alternative
methods to effectively treat melanoma need to be developed.
We found that MELK is a survival kinase for melanoma and
that MELK inhibition, by either genetic or pharmacological
methods, blocked growth of melanoma cells. Furthermore,
MELK inhibition in melanoma cells inhibited tumor growth in a
variety of genotypes, including BRAF mutant, NRAS mutant,
and NF1-deficient melanoma. In addition, vemurafenib-resistant
melanoma cells were sensitive to MELK inhibitors, and we
observed that MELK inhibitors forestalled the emergence of ve-
murafenib resistance in melanoma cells. MELK knockout mice
are viable and do not show obvious defects. Altogether, these
observations suggest that MELK is an important and broadly
applicable therapeutic target in melanoma.
MELKRegulates a LargeNumber of Previously Reported
BRAF-MEK-ERK Substrates
MELK is a serine/threonine protein kinase that regulates the cell
cycle, stem cell renewal, and apoptosis (Badouel et al., 2006;
Davezac et al., 2002; Jung et al., 2008; Nakano et al., 2005). Pre-
vious studies have identified some MELK substrates, including
ASK1, ZNF622, BCL2L14, and CDC25B (Davezac et al., 2002;
Jung et al., 2008; Lin et al., 2007; Seong et al., 2002). The
apoptotic functions of MELK are mediated by ASK1 and
BCL2L14 regulation (Jung et al., 2008; Lin et al., 2007), while
its cell-cycle regulatory effects are proposed to be mediated
by its phosphorylation of CDC25B (Davezac et al., 2002; Mirey
et al., 2005). In addition to regulating apoptosis and the cell
cycle, MELK regulates other aspects of cell biology. For
example, MELK has been shown to inhibit spliceosome assem-
bly during mitosis by phosphorylating ZNF622, thereby contrib-
uting to its redirection to the nucleus. Using SILAC, we identified
469 proteins with downregulated phosphorylation after MELK in-
hibition. In addition, a large number of proteins (139 proteins)
were previously identified as potential MEK and BRAF sub-
strates (Galan et al., 2014; Stuart et al., 2015). Because MELK
expression is regulated by the MAPK pathway, these findings
suggest MELK is a major mediator of MAPK pathway function
that promotes melanoma growth.
MELK Is a Regulator of the NF-kB Pathway
The NF-kB pathway is a major tumor promotion pathway in mel-
anoma and several other cancer types (Dhawan and Richmond,
2002; Erstad and Cusack, 2013; Liu et al., 2015; Madonna et al.,
2012; Pikarsky et al., 2004). We found that MELK regulates the
NF-kB pathway by phosphorylating SQSTM1/p62, which is
consistent with a previous study that showed that SQSTM1 is
important for NF-kB-mediated tumorigenesis (Duran et al.,
2008). In addition, we demonstrated that MELK inhibition
decreased the expression of NF-kB transcriptional targets, and
we partially rescued diminished melanoma growth after MELK
inhibition by expressing IKKb CA. Altogether, these results iden-
tify MELK as a regulator of the NF-kB pathway and show that
(C) (Left) A375 and M14 cells were transfected with the NF-kB-responsive F-Luc construct, treated with OTSSP167 (50 nM) for 24 hr, and analyzed for firefly
luciferase activity. Relative firefly luciferase activity under indicated conditions is shown. (Right) A375 cells expressingMELK shRNAs were transfected with the
NF-kB-responsive F-Luc construct, either remained untreated or were treated with doxycycline, and were analyzed for firefly luciferase activity. Relative firefly
luciferase activity under indicated conditions is shown.
(D) Indicated NF-kB target genes were analyzed by qRT-PCR in A375 cells expressingMELK shRNAs that were either left untreated or treated with doxycycline
(2 mg/mL) for 72 hr. Relative mRNA expression for the indicated gene in relation to NS shRNA-expressing cells is shown.
(E) A375 cells were treated with either DMSO or OTSSP167 (50 nM) for 24 hr. Relative mRNA expression for indicated NF-kB target genes compared to DMSO-
treated cells is shown.
(F) Co-immunoprecipitation was performed using either MELK or, as a control, IgG antibodies. Immunoprecipitate and input were analyzed for indicated proteins.
(G) In vitro kinase assay was performed to determine the ability of recombinant MELK to phosphorylate SQSTM1. The autoradiograph for P32-labeled SQSTM1 is
shown, and the western blots for SQSTM1 and MELK are shown as controls.
(H) In vitro kinase assay using MELK inhibitor (left, OTSSP167 [50 nM]; right, MELK-8a [500 nM]) was performed. The autoradiograph for P32-labeled SQSTM1 is
shown, and the western blot for SQSTM1 and MELK is shown.
(I) A375 cells expressing either non-silencing (NS) orSQSTM1 shRNAswere analyzed for indicated proteins using immunoblotting. ACTINBwas used as a loading
control.
(J) A375 cells expressing SQSTM1 shRNAs were transfected with the NF-kB-responsive F-Luc construct and analyzed for firefly luciferase activity 48 hr after
transfection. Relative firefly luciferase activity under indicated conditions is shown.
(K) A375 cells expressing NS or SQSTM1 shRNAs were analyzed for the indicated NF-kB target genes by qRT-PCR analysis. Relative mRNA expression is for the
indicated genes in SQSTM1 shRNA-expressing cells relative to NS shRNA-expressing cells.
Data are presented as ±SD for three biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S6.
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Figure 6. Overexpression of IKKb CA Restores NF-kB Signaling in MELK-Inhibited Melanoma Cells
(A and B) (Left) A375 cells expressing doxycycline-inducibleMELK shRNA#1 (A) orMELK shRNA#2 (B) were transfected with constitutively active IKKb (IKKbCA)
or empty vector. Cells were either untreated or treated with doxycycline (2 mg/mL) for 72 hr and analyzed for indicated proteins by immunoblot analysis. ACTINB
was used as a loading control. (Right) A375 cells expressing MELK shRNA#1 (A) orMELK shRNA#2 (B) were transfected with IKKb CA or empty vector and the
NF-kB-responsive F-Luc construct. Cells either remained untreated or were treated with doxycycline and analyzed for firefly luciferase activity. Relative firefly
luciferase activity under indicated conditions is shown.
(C) (Left) A375 cells were transfected with constitutively active IKKb (IKKb CA) or empty vector, subsequently treated with either DMSO or OTSSP167 (50 nM) for
24 hr, and analyzed for indicated proteins by immunoblot analysis. ACTINB was used as a loading control. (Right) A375 cells were transfected with IKKb CA or
empty vector and the NF-kB-responsive F-Luc construct, treated with OTSSP167 (50 nM) for 24 hr, and analyzed for firefly luciferase activity. Relative firefly
luciferase activity for indicated conditions is shown.
(D) A375 cells expressing SQSTM1 shRNA were transfected with constitutively active IKKb (IKKb CA) or empty vector and analyzed for indicated proteins by
immunoblot analysis 48 hr after transfection. ACTINB was used as a loading control.
(E) A375melanoma cells were transfectedwith constitutively active IKKb (IKKbCA) or empty vector, treatedwithOTSSP167 (25 nM), and analyzed for anchorage-
independent growth using soft-agar assay. Representative images for soft-agar colonies for indicated melanoma cell lines for the indicated treatment conditions
are shown. Scale bar, 200 mm.
(F) Relative colony size (%) for A375 cells expressing empty vector or constitutively active IKKb were DMSO or OTSSP167 (25 nM) treated.
Data are presented as ±SD for three biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001.
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MELK at least partly promotes melanoma growth by activating
the NF-kB pathway.
EXPERIMENTAL PROCEDURES
Cell Culture
A375, M14, SKMEL28, and MeWo cell lines were obtained from the American
Type Culture Collection (ATCC). YUGASP cells were obtained from Yale
SPORE in Skin Cancer. SKMEL239 cell lines (parental and vemurafenib-resis-
tant) were described previously (Poulikakos et al., 2011) and were a gift from
Drs. David Solit and Neal Rosen. A375, MeWo, and YUGASP were grown in
DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin
and streptomycin (PenStrep) antibiotics. M14, SKMEL28, and SKMEL239
were grown in RPMI supplemented with 10% FBS and 1% PenStrep
antibiotics.
Cell Labeling and SILAC Analysis
Cells were seeded at 15% confluency in the respective complete medium (for
A375, DMEM + 10% dialyzed FBS, 1% PenStrep; for M14, RPMI + 10% dia-
lyzed FBS, 1% PenStrep). All media was deficient in lysine and arginine and
supplemented with light- or heavy-labeled lysine (13C6
15N2) and light- or
heavy-labeled arginine (13C6
15N4). Cells were subsequently cultured for at
least five doublings in light or heavy medium, which achieved more than
95% labeling efficiency for us in pilot experiments. After labeling, cells were
treated for 24 hr with 25 nM (A375) or 50 nM (M14) of OTSSP167. After treat-
ment, cells were trypsinized and counted to obtain a cell pellet of 23 107 cells/
condition and subjected to SILAC analysis using mass spectrometry.
Sample Preparation
The heavy and light cell pellets were lysed in RIPA buffer spiked with protease
and phosphatase inhibitors using short 15 s sonication bursts. Lysates were
centrifuged at 14,000 rpm for 20 min. After centrifugation, the supernatants
were collected and the protein concentration was measured using a Hitachi
L-8900 Amino Acid Analyzer. From each sample, 200 mg of proteins were
aliquoted, combined, and precipitated using amethanol-chloroform precipita-
tion method. The protein pellets were resuspended in 8 M urea/0.4 M ammo-
nium bicarbonate buffer, reduced with 45 mM DTT for 30 min at 37C,
alkylated with 100 mM iodoacetamide for 30 min in the dark at room temper-
ature, and digested with Lys-C protease (1:20 w/w) by incubating overnight
(16 hr) at 37C. The Lys-C digest was further diluted and digestedwith trypsin
(1:20 w/w) by incubating for 8 hr at 37C. The digest was desalted with a
MacroSpin column (The Nest Group, Southborough, MA) and dried down
in a SpeedVac concentrator. Desalted peptides were then phosphopeptide
enriched using titanium dioxide resin imbedded in 10-mL tips (Glygen,
Columbia, MD). Flowthroughs were reserved and enriched peptides were
eluted using 1:33 ammonium hydroxide/water. The SpeedVac dried flow-
through and elution fractions were resuspended in buffer A (0.1% formic
acid in water) and subjected to liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) analysis.
Mass Spectrometry Data Acquisition and Analysis
The samples were analyzed by LC-MS/MS on an Orbitrap Fusion Tribrid
mass spectrometer (Thermo Scientific, San Jose, CA) interfaced with a nano-
Acquity UPLC System (Waters, Milford, MA) at the front end. Samples were
loaded into a trapping column (nanoAcquity UPLC Symmetry C18 Trap Col-
umn, 180 mm 3 20 mm, product 186006527) at a flowrate of 5 mL/min and
separated with a C18 column (Peptide BEH C18 nanoAcquity Column,
75 mm 3 250 mm, product 186003545). The peptides were eluted with
buffer B (0.1% formic acid in acetonitrile) in a gradient from 6% to 35% in
150 min at a flowrate of 300 nL/min. LC-MS/MS data were acquired using
3 s, the top-speed, data-dependent acquisition mode. Details of the instru-
ment settings can be found in the Supplemental Information.
Peptides and proteins were identified and quantified with the Sequest HT
search engine using Proteome Discoverer v.2.1 software (Thermo Scientific).
A standardized SILAC 2plex (Arg10 and Lys8) quantification workflow in the
Proteome Discoverer was slightly modified and used for analysis. Briefly,
MS/MS data were searched against the SwissProt human database (down-
loaded in September 2015; number of protein entries = 20,193). In the Peak Fil-
ters node, the signal to noise ratio (S/N) threshold was set to 1.5. The search
criteria included 10 ppm precursor mass tolerance, 0.02 Da fragment mass
tolerance, and a trypsin miscleavage setting of 2. Static modification settings
included carbamidomethylation (+57.021 Da) on cysteine, while dynamic
modifications were set to include oxidation (+15.995 Da) on methionine and
phosphorylation (+79.966 Da) on serine, threonine, and tyrosine. Peptide
spectrum matches (PSMs) were verified based on q values set to a 1% false
discovery rate (FDR) using Percolator. The Precursor Ions Quantifier node
was used in the processing step workflow, and the Peptide and Protein Quan-
tifier node was selected for the consensus workflow to calculate and quantify
peptides, protein abundances, and ratios. The PhosphoRS node (Taus et al.,
2011) was used to obtain the localization probability of the phosphorylation
sites in the peptides.
SILAC Data Analysis for Identifying the Preferred MELK Amino Acid
Context for Phosphorylation
A cutoff of two-fold was used to define downregulation of the phosphorylation
level for validation experiments. To identify the MELK phosphorylation
consensus site from the SILAC data, we used a prediction algorithm devel-
oped in house. The motifs were generated by the R/Bioconductor package
dagLogo (v.1.9.2). The background of themotifs was built from the human pro-
teome retrieved via the R/Bioconductor package UniProt.ws (v.2.11.9). Lists of
all quantified phosphopeptides are presented in Table S4 (for the A375 cell
line) and Table S5 (for the M14 cell line). The SILAC proteomics data have
been submitted to PRIDE (https://www.ebi.ac.uk/pride/archive/). The acces-
sion number for these data is PRIDE: PXD007872.
Melanoma Data Analysis
The Talantov melanoma dataset (Talantov et al., 2005), Riker melanoma da-
taset (Riker et al., 2008), and Xu melanoma dataset (Xu et al., 2008) were
analyzed for MELK expression using Oncomine (https://www.oncomine.
org/resource/login.html), and MELK expression across different samples
Figure 7. Model Elucidating the Role of MELK in Melanoma
Activated MAPK signaling pathway leads to the upregulation of MELK
expression via the transcription factor E2F1. MELK phosphorylates the
adaptor protein SQSTM1, which in turn stimulates the NF-kB pathway activity
necessary for stimulating melanoma growth.
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was plotted as boxplots. In addition, three previously published melanoma
gene expression datasets were analyzed for MELK expression and plotted
as boxplots (Eskiocak et al., 2016; Kabbarah et al., 2010; Scatolini et al.,
2010).
Statistical Analysis
All quantitative data were collected from experiments performed in at least
triplicate and expressed as mean ± SD. Differences between groups were as-
sayed with Student’s t test using GraphPad Prism v.6.0h for Macintosh
(GraphPad, San Diego, CA) (https://www.graphpad.com/). Significant differ-
ences were considered when p% 0.05.
DATA AND SOFTWARE AVAILABILITY
The accession number for the SILAC proteomics data reported in this paper is
PRIDE: PXD007872.
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